Latest Stock Buy or Sell? Make More Informed Decisions!
Today, The Panic-Proof Portfolio (Stockchase Research) and Michelle Wearing commented about whether CHCT, AMH, COLD, CAR.UN.TO, AP.UN.TO, XRE.TO, CSH.UN.TO, CRR.UN.TO, NWH.UN.TO, ERE.UN.TO, KMP.UN.TO, PLD, CRT.UN.TO, SPG, SRU.UN.TO, HR.UN.TO, CUF.UN.TO, GRT.UN.TO, IIP.UN.TO, OMF, MTG, TCF, BIIB, NLOK, CVS are stocks to buy or sell.
- Page 1/2
- Next Page
'%20fill='%23000000'%3e%3cg%20id='Rating-Card'%20transform='translate(120.000000,%20487.000000)'%3e%3cpath%20d='M848.295367,82.286474%20C848.68919,81.9045087%20849.327703,81.9045087%20849.721525,82.286474%20L854,86.4361302%20L858.278475,82.286474%20C858.672297,81.9045087%20859.31081,81.9045087%20859.704633,82.286474%20C860.098456,82.6684393%20860.098456,83.2877274%20859.704633,83.6696927%20L854.35654,88.856763%20C854.159628,89.0477457%20853.840372,89.0477457%20853.64346,88.856763%20L848.295367,83.6696927%20C847.901544,83.2877274%20847.901544,82.6684393%20848.295367,82.286474%20Z'%20id='Path'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium content
Premium content
Stockchase Research Editor: Michael O'Reilly BIIB has been on a roller-coaster. When the FDA announced a priority review of a new Alzheimer's drug, it stock soared to $360. When the review failed to approve the drug in the first go-round, the stock plunged to under $250 -- so it goes with drug manufacturers. Its MS drugs continue to do well and it is working on treatments for Parkinson's disease as well. Trading at 8x earnings, it is cheap compared to peers at 30x. We would buy this with a $180 stop-loss looking to achieve $305 -- 26% upside. Yield 0%. (Analysts’ price target is $305.90)
Premium content
Premium content
Premium content
Michelle Wearing
Focus on Walmart and adjacent retail. Likes Walmart, but the adjacent retail faces headwinds. Management team says better growth in residential than in retail. She'd take this cue and invest in companies that already have residential exposure. Talk of distribution cut.
%20-%20http://www.bohemiancoding.com/sketch%20--%3e%3ctitle%3ePath%205%3c/title%3e%3cdesc%3eCreated%20with%20Sketch.%3c/desc%3e%3cg%20id='Page-1'%20stroke='none'%20stroke-width='1'%20fill='none'%20fill-rule='evenodd'%20stroke-linecap='round'%20stroke-linejoin='round'%3e%3cg%20id='mobile'%20transform='translate(-353.000000,%20-32.000000)'%20stroke='%2325292B'%20stroke-width='1.5'%3e%3cg%20id='Group'%20transform='translate(321.000000,%2022.000000)'%3e%3cpath%20d='M33,11%20L36.2928932,14.2928932%20C36.6834175,14.6834175%2037.3165825,14.6834175%2037.7071068,14.2928932%20L41,11'%20id='Path-5'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Most popular stocks on Stockchase
- Toronto-Dominion Bank (TD.TO)
- Enbridge (ENB.TO)
- BCE Inc. (BCE.TO)
- Manulife Financial (MFC.TO)
- Bank of Nova Scotia (BNS.TO)
- Apple Inc (AAPL)
- Suncor Energy Inc (SU.TO)
- Microsoft Corp (MSFT)
- Canadian Natural Rsrcs (CNQ.TO)
- Royal Bank (RY.TO)
- Telus Corp (T.TO)
- TC Energy (TRP.TO)
- Alphabet Inc (GOOG)
- Canadian National R.R. (CNR.TO)
- Crescent Point Energy Corp (CPG.TO)
- Amazon.com, Inc. (AMZN)
- Teck Resources Ltd. (B) (TECK.B.TO)
- BlackBerry (BB.TO)
- Fortis Inc. (FTS.TO)
- Canadian Imperial Bank of Commerce (CM.TO)
- Bank of Montreal (BMO.TO)
- NVIDIA Corporation (NVDA)
- Bank of America (BAC)
- Bombardier Inc (B) (BBD.B.TO)
- Algonquin Power & Utilities Corp (AQN.TO)
- Pembina Pipeline Corp (PPL.TO)
- Meta Platforms Inc (META)
- Walt Disney Co. (DIS)
- Sun Life Financial Inc (SLF.TO)
- Arc Resources Ltd (ARX.TO)
Stockchase Research Editor: Michael O'Reilly CVS, the 2nd largest pharmacy in the US, recently came under pressure with the announcement of Amazon stepping into the pharmacy space. However, now trading at 11x earnings, CVS is good value here -- especially after announcing they are hiring 15,000 staff in Q4 to likely become a mass vaccine distributor. Recent earnings of $1.66 per share beat expectations of $1.34. Management raised guidance of annual 2020 earnings to $7.35-$7.42 per share, above analyst calls for $7.23. It pays a great dividend, backed by a 33% payout ratio. We would buy this with a stop-loss at $57, looking to achieve over $82 -- over 21% potential. Yield 2.96% (Analysts’ price target is $82.43)